Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
ACG Case Rep J ; 10(12): e01206, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38033616

RESUMO

We describe a case of hepatoportal sclerosis (HPS) identified in an 81-year-old woman taking a traditional Chinese herbal supplementation, Cordyceps. The patient presented with splenomegaly and weight loss. After an extensive evaluation, liver biopsy confirmed loss of the small portal veins with characteristics of obstruction at the level of the small and large portal veins, suggestive of HPS. After a comprehensive history and exclusion of other etiological factors, patient's HPS was attributed to Cordyceps use. Ultimately, the patient's features of HPS improved with the cessation of Cordyceps.

2.
Free Radic Biol Med ; 77: 168-82, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25224033

RESUMO

The contribution of oxidative stress to ischemic brain damage is well established. Nevertheless, for unknown reasons, several clinically tested antioxidant therapies have failed to show benefits in human stroke. Based on our previous in vitro work, we hypothesized that the neuroprotective potency of antioxidants is related to their ability to limit the release of the excitotoxic amino acids glutamate and aspartate. We explored the effects of two antioxidants, tempol and edaravone, on amino acid release in the brain cortex, in a rat model of transient occlusion of the middle cerebral artery (MCAo). Amino acid levels were quantified using a microdialysis approach, with the probe positioned in the ischemic penumbra as verified by a laser Doppler technique. Two-hour MCAo triggered a dramatic increase in the levels of glutamate, aspartate, taurine, and alanine. Microdialysate delivery of 10mM tempol reduced the amino acid release by 60-80%, whereas matching levels of edaravone had no effect. In line with these data, an intracerebroventricular injection of tempol but not edaravone (500 nmol each, 15 min before MCAo) reduced infarction volumes by ~50% and improved neurobehavioral outcomes. In vitro assays showed that tempol was superior at removing superoxide anion, whereas edaravone was more potent at scavenging hydrogen peroxide, hydroxyl radical, and peroxynitrite. Overall, our data suggest that the neuroprotective properties of tempol are probably related to its ability to reduce tissue levels of the superoxide anion and pathological glutamate release and, in such a way, limit progression of brain infarction within ischemic penumbra. These new findings may be instrumental in developing new antioxidant therapies for treatment of stroke.


Assuntos
Óxidos N-Cíclicos/farmacologia , Ácido Glutâmico/metabolismo , Infarto da Artéria Cerebral Média/tratamento farmacológico , Fármacos Neuroprotetores/farmacologia , Alanina/metabolismo , Animais , Antipirina/análogos & derivados , Antipirina/química , Antipirina/farmacologia , Astrócitos/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Células Cultivadas , Óxidos N-Cíclicos/química , Avaliação Pré-Clínica de Medicamentos , Edaravone , Sequestradores de Radicais Livres/química , Sequestradores de Radicais Livres/farmacologia , Infarto da Artéria Cerebral Média/metabolismo , Infarto da Artéria Cerebral Média/patologia , Masculino , Mimetismo Molecular , Fármacos Neuroprotetores/química , Estresse Oxidativo , Ratos Sprague-Dawley , Marcadores de Spin , Superóxidos/metabolismo , Sinaptossomos/efeitos dos fármacos , Taurina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA